# name
Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

# metadata.dc.description.abstract[].value
The RTS,S/AS01 - " vaccine has shown consistent but partial
                vaccine efficacy in a pediatric phase 3 clinical trial using a
                3-dose immunization schedule. A fourth-dose 18 months after the
                primary vaccination was shown to restore the waning efficacy.
                However, only total IgG against the immunodominant malaria
                vaccine epitope has been analyzed following the booster. To
                better characterize the magnitude, nature, and longevity of the
                immune response to the booster, we measured levels of total IgM,
                IgG, and IgG" - " subclasses against three constructs of the
                circumsporozoite protein (CSP) and the hepatitis B surface
                antigen (HBsAg, also present in RTS,S) by quantitative
                suspension array technology in 50 subjects in the phase 3 trial
                in Manhi\xC3\xA7a, Mozambique. To explore the impact of
                vaccination on naturally acquired immune responses, we measured
                antibodies to " - " antigens not included in RTS,S. We found
                increased IgG, IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels
                against vaccine antigens 1 month after the fourth dose. Overall,
                antibody responses to the booster dose were lower than the
                initial peak response to primary immunization and children had
                higher IgG and IgG1 levels than infants. Higher anti-Rh5 IgG and
                IgG" - " levels were detected after the booster dose, suggesting
                that RTS,S partial protection could increase some blood stage
                antibody responses. Our work shows that the response to the
                RTS,S/AS01" - " booster dose is different from the primary
                vaccine immune response and highlights the dynamic changes in
                subclass antibody patterns upon the vaccine booster and with
                acquisition of adaptive immunity to malaria."

# metadata.dc.publisher[].value
[London] : Springer Nature in partnership with the Sealy Center
                for Vaccine Development, [2016]-

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique